Chemomab Therapeutics GAAP每股收益为0.00美元

2025-11-20 21:33

Chemomab Therapeutics press release (CMMB): Q3 GAAP EPS of $0.00.
Net loss was $1.7 million, or a net loss of less than one-half of one cent per basic and diluted ordinary share for the third quarter of 2025, compared to a net loss of $3.5 million, or a net loss of approximately $0.01 per basic and diluted ordinary share, for the third quarter of 2024.
Cash, cash equivalents and short-term bank deposits were $10.2 million as of September 30, 2025, compared to $9.5 million as of June 30, 2025 and $14.2 million as of December 31, 2024.

More on Chemomab Therapeutics